Netflix to Acquire Ben Affleck’s AI Firm in $600M Deal

Netflix is acquiring Ben Affleck’s AI filmmaking company InterPositive for up to $600 million, marking one of its largest tech-driven bets yet. The cash portion is lower, with additional payouts tied to performance milestones, signaling Hollywood’s growing embrace of AI-powered content creation.

Post acquisition, Netflix will be bringing its 16‑person team into the streaming giant.  

Key Details of the Deal

• Company: InterPositive, founded by Ben Affleck in 2022
• Acquisition Price: Up to $600 million (cash + performance-based earnouts)
• Purpose: Accelerate Netflix’s use of AI in filmmaking
• Capabilities:
  • AI tools to maintain cinematic logic
  • Automated fixes for production issues (e.g., lighting errors)
• Context: Netflix recently lost a bid for Warner Bros. Discovery, making this deal a strategic pivot toward proprietary tech

Why This Matters

• Hollywood Shift: The deal underscores how major studios are warming to AI-generated or AI-assisted content.
• Creative Control: InterPositive’s tech is designed to support filmmakers rather than replace them, ensuring artistic integrity while reducing costs.
• Strategic Edge: Netflix gains exclusive access to AI filmmaking tools, potentially lowering production timelines and budgets.

Comparison: Netflix vs. Competitors in AI Adoption

Company	AI Strategy	Recent Moves
Netflix	Proprietary AI filmmaking via InterPositive	$600M acquisition of Affleck’s firm
Disney	AI for VFX and crowd simulations	Internal R&D, no major acquisitions
Warner Bros.	Exploring AI for script analysis	Focused on partnerships, not acquisitions
Amazon Prime	AI-driven recommendation & production planning	Heavy investment in predictive analytics

Risks & Challenges

• Creative Backlash: Filmmakers may resist AI involvement, fearing dilution of artistry.
• Regulatory Scrutiny: AI in media raises copyright and labor concerns.
• Execution Risk: InterPositive must hit performance targets for full payout.

What’s Next

• Expect Netflix to integrate AI into original productions by 2027, starting with mid-budget films.
• This move could reshape Hollywood workflows, making AI a standard tool in editing, continuity, and production design.
• Affleck’s dual role as a filmmaker and tech founder positions him as a bridge between creative and technological communities.

Interpositive Profile 

InterPositive is a Los Angeles‑based AI filmmaking startup founded by Ben Affleck in 2022. It focuses on AI tools that assist filmmakers in post‑production, continuity, and creative support. 

Core AI Capabilities

• Continuity Management: Detects inconsistencies in props, lighting, or wardrobe and suggests fixes before editing.
• Scene Optimization: Models cinematic logic to align camera angles, pacing, and transitions with storytelling conventions.
• Automated Corrections: Digitally adjusts lighting, color grading, or minor background elements to maintain realism.
• Production Efficiency: Flags errors early to reduce costly reshoots and accelerate post-production timelines.

Example in Practice

• Day 1: Actor’s coffee cup is half-full.
• Day 2: Cup is suddenly empty in the same sequence.
• AI Fix: Detects mismatch, alerts editor, and either recommends reshoot or digitally adjusts the cup for continuity.

Why Netflix Wants This

• Cost Savings: Reshoots can cost millions; AI fixes are cheaper.
• Scalability: Netflix produces hundreds of originals annually—AI ensures consistency across massive output.
• Creative Support: Affleck emphasizes AI is assistive, not a replacement, keeping directors in control.

Future Outlook

Netflix will roll out AI-assisted workflows first in mid-budget dramas and thrillers. Expansion into big-budget blockbusters is expected, especially for VFX-heavy productions. Affleck’s involvement positions the tech as a filmmaker’s ally, not a threat to artistry.

India’s $58 Billion Trade Surplus Sparks US Probe

Image - #UNGA/Flickr

The United States has formally launched a Section 301 trade probe into India, citing a record $58 billion trade surplus and alleged “structural excess capacity” in key industries such as steel, petrochemicals, textiles, autos, and solar modules. This investigation could lead to new tariffs and complicates ongoing India–US trade negotiations.

Key Details

• Probe Basis: Section 301 of the US Trade Act, often used to investigate unfair trade practices.
• Targeted Countries: India plus 15 other major US trading partners, including China.
• Reason: US claims India’s industrial overproduction displaces American manufacturing and discourages domestic investment.
• Trade Surplus Highlighted: India recorded a $58 billion surplus with the US in 2025, making it a prime target.
• Recent Context: In February 2026, Washington and New Delhi agreed to reduce US tariffs on Indian goods from 50% to 18%, but this probe now threatens that progress.

Impact on India–US Trade Relations

Factor	Current Status	Potential Impact
Tariffs	Reduced to 18% in Feb 2026	Could rise again if probe finds unfair practices
Bilateral Trade Agreement (BTA)	Ongoing negotiations	May stall due to tariff uncertainty
Industries at Risk	Steel, petrochemicals, solar modules, textiles, autos	Higher tariffs, reduced exports
US Domestic Politics	Driven by Trump’s “America First” agenda	Increased protectionism, pressure on India

Risks & Challenges

• Tariff Escalation: If the US imposes new duties, Indian exporters in steel, petrochemicals, and solar could face sharp declines in competitiveness.
• Diplomatic Strain: The probe may slow or derail bilateral trade agreement talks, undermining recent progress.
• Global Supply Chains: India’s role in supplying affordable solar modules and steel could be disrupted, affecting global markets.
• Legal Uncertainty: The US Supreme Court recently invalidated reciprocal tariffs, giving the administration more leeway to impose unilateral measures.

Strategic Outlook

• India’s Position: Likely to argue that its production capacity supports global demand and is not aimed at undermining US industry.
• US Strategy: Using Section 301 probes as leverage to secure concessions in trade negotiations.
• Global Implications: Other countries targeted (like China) may coordinate responses, potentially escalating trade tensions worldwide.

OneKiraana Raises $1.6M led by Ankur Capital

OneKiraana, a startup enabling India’s kirana stores to create their own private labels through customization at the micro-layer, announced it has raised $1.6 million in seed funding led by Ankur Capital. This round also saw participation from GreenTrunk Ventures, VCMint and other angel investors.

The fresh capital will be deployed to expand OneKiraana’s tech and manufacturing capabilities, deepen its last-mile logistics network, and grow its store footprint across India. The company is currently working with 900+ kirana stores, with over 3M private labelled products supplied in 1500 SKUs across 25 categories.

India’s $500 billion grocery market remains largely offline, served by 13 million neighborhood kirana stores. Yet these stores have long operated with fragmented supply chains, limited pricing power, and no meaningful brand identity of their own. OneKiraana’s platform is changing that, through a combination of SKU customization at micro-layer, last-mile logistics, and data-driven optimization to reshape local commerce.

By working closely with stores, OneKiraana captures SKU-level sales velocity, pricing behavior, regional preferences, and working capital cycles. Through integrations with hyperlocal logistics providers, OneKiraana plans to power home delivery for kirana stores, without fixed staffing costs. This data captured feeds directly into sourcing, production planning, distribution and pricing decisions - creating an intelligence layer that learns and improves continuously.

“We started OneKiraana with the belief that kiranas need foundational infrastructure to thrive in a world where consumer expectations around quality, packaging and delivery are rapidly changing”, said Bhavin Soni, Co-Founder and CEO, OneKiraana. ”The opportunity is clear: kiranas that upgrade their offerings with the right technology infrastructure - better products, efficient distribution, and enabling intelligence layer - will capture the next wave of consumption and emerge as 'bright stores' in their neighborhoods. Today, we’re building the rails - product, mass customization and hyperlocal intelligence - enabling kiranas to build their own brand identity and get control over pricing, aligning our success with retailer success. Over the next 18 months, we will build the end-to-end operating system that lets every neighborhood store compete like a scaled retailer.”

Rema Subramanian, Managing Partner at Ankur Capital, added “At Ankur Capital, we look for opportunities where technological shifts create new opportunities at scale. We’re at a fascinating inflection point in the Indian grocery retail landscape, and OneKiraana is building the complete infrastructure layer that enables mass customization for kirana stores. Technology that enables better products customized to local needs, efficient distribution to pass value to store owners, and last-mile delivery - these three rails working together create a compounding advantage that was earlier only available to larger organized retailers.”

About OneKiraana

OneKiraana is a tech platform enabling India’s kirana stores to launch private-label products, optimize inventory through demand intelligence, and offer home delivery via third-party logistics. Starting with 900+ stores, the company is building a distributed intelligence network for India’s most fragmented retail segment. For more information, visit www.onekiraana.com.

About Ankur Capital

Founded in 2014, Ankur Capital is an early-stage venture capital firm in India, investing in digital and deep science technology companies. Ankur Capital has backed over 30 companies across sectors including category leaders such as Captain Fresh (B2B Commerce), Vegrow (B2B Commerce), StringBio (Synthetic biology), Turiyam (Semiconductors), Craftif (Edge AI), OffGrid Energy (Battery Chemistry), Agrizy (B2B Commerce), Superfone (Neo-telco) and Niramai (AI Medtech) among others. The firm has offices in Mumbai, Delhi and Bangalore. More at www.ankurcapital.com

Bank of Baroda Raises $500 Mn 5-Year Syndicated Loan; Attracts Strong Participation from Asian Investors

Bank of Baroda, India’s International Bank, through its IFSC Banking Unit in GIFT City, has successfully closed a USD 500 million five-year syndicated term loan facility. The transaction saw participation from 13 investors across key Asian markets including Taiwan, South Korea, Japan and Singapore, reflecting robust demand and strong investor appetite, despite a dynamic global interest rate environment.

The facility also advances the Bank’s strategy to broaden its global investor base, with increased participation from investors in Asia, thereby diversifying its funding sources and complementing the Bank’s traditional domestic investor base, who remain active participants in the Bank’s local currency issuances.

This transaction marks the Bank’s return to the global syndicated loan market after a gap of one year. The proceeds of the facility will be used for general banking and corporate purposes. MUFG Bank and HSBC acted as Mandated Lead Arrangers, Underwriters, and Bookrunners.

Dr. Debadatta Chand, Managing Director & CEO, Bank of Baroda said, “This successful transaction reinforces the confidence that global institutions place in Bank of Baroda’s prudent financial management and long-term strategic direction. The strong participation from investors across Asia reflects growing international interest in the Bank and supports our continued focus on diversifying funding sources, strengthening global investor engagement and further cementing our standing as India’s international bank."

Bank of Baroda maintains strong international credit ratings. The Bank was recently assigned ‘BBB’ long-term and ‘A-2’ short-term issuer credit ratings with a Stable Outlook by S&P Global Ratings, in line with the sovereign rating of the Government of India. The Bank is also rated ‘BBB-’ with a Stable Outlook by Fitch Ratings, which recently upgraded its Viability Rating to ‘bb’ from ‘bb-’. Moody’s Investors Service has assigned the Bank a ‘Baa3’ rating with a Stable Outlook.

Bank of Baroda is one of India’s leading public sector banks, with a global presence spanning 80 overseas branches/offices in 15 countries, including major international financial centres such as New York, London, Dubai and Singapore. As of 31st December 2025, the Bank’s total international business stood at INR 4,879.08 billion, accounting for 16.08% of the Bank’s Global Business. International Deposits stood at INR 2,395.60 billion, while International Advances stood at INR 2,483.48 billion.

About Bank of Baroda

Founded on 20th July, 1908 by Sir Maharaja Sayajirao Gaekwad III, Bank of Baroda is one of the leading commercial banks in India. At 63.97% stake, it is majorly owned by the Government of India. The Bank serves its global customer base of over ~180 million through around 65,000 touch points spread across 15 countries in five continents and through its various digital banking platforms, which provide all banking products and services in a seamless and hassle-free manner. The Bank’s vision matches the aspirations of its diverse clientele base and seeks to instil a sense of trust and security in all their dealings with the Bank.

World Kidney Day 2026: Experts Urge Early Screening as Chronic Kidney Disease Affects 1 in 10 People Globally

On the occasion of World Kidney Day, Mankind Pharma, in association with leading healthcare experts, is calling for greater awareness around kidney health, highlighting that chronic kidney disease (CKD) affects nearly 10% of the global population and is often detected only at advanced stages due to the absence of early warning signs.

Kidneys play a vital role in maintaining overall health by filtering waste, balancing fluids, regulating blood pressure and supporting several metabolic functions in the body. However, one of the biggest challenges with kidney disease is that it often develops silently. Medical experts warn that an individual can lose up to 90% of kidney function without noticeable symptoms, making early screening and preventive care critical.

As part of its World Kidney Day initiative, Mankind Pharma is promoting awareness around kidney health and the importance of early detection through educational outreach and expert-led discussions. The initiative also focuses on encouraging individuals to proactively monitor key health indicators such as blood pressure, blood sugar and kidney function through simple diagnostic tests.

India is currently facing a growing kidney health crisis. According to global health studies, nearly 138 million people in India are living with chronic kidney disease, making it the second-highest burden of CKD globally. Research also suggests that 13–17% of adults in the country may be living with some stage of kidney disease, many of whom remain undiagnosed until the condition has significantly progressed.

The treatment burden is equally concerning. Experts estimate that India requires nearly 200,000 kidney transplants every year, but only about 13,500 transplants are performed, meeting less than 6% of the actual demand. The shortage of organ donors continues to be a major challenge, with India’s organ donation rate remaining below one donor per million population, far lower than many developed nations. In India, the rising prevalence of diabetes and hypertension continues to drive the growing burden of chronic kidney disease. Lifestyle factors such as high-salt diets, unhealthy eating habits and sedentary lifestyles further increase the risk. With India often referred to as the diabetes capital of the world, experts emphasise that individuals with diabetes, high blood pressure, obesity or a family history of kidney disease must be particularly vigilant about regular health check-ups.

Dr. Anant Kumar, Chairman – Urology, Renal Transplant and Robotics, Max Saket Complex and Uro-Oncology, MSSH Saket, said

Chronic kidney disease often progresses silently and remains undetected until it reaches advanced stages. Individuals with diabetes, high blood pressure, obesity or a family history of kidney disease should undergo regular screening through simple tests such as blood creatinine, urine analysis and blood pressure monitoring. Early diagnosis plays a crucial role in slowing the progression of the disease and improving patient outcomes.

Arjun Juneja, COO, Mankind Pharma said,

World Kidney Day serves as an important reminder that prevention and early detection are key to tackling the growing burden of kidney disease. By encouraging regular health screenings, promoting healthier lifestyle choices and raising awareness about kidney health, we aim to empower individuals to take proactive steps toward protecting their long-term health.

As part of the awareness campaign, the company is also highlighting the importance of following simple preventive practices for kidney health. These include staying physically active, maintaining healthy blood sugar levels, regularly monitoring blood pressure, following a balanced diet with controlled salt intake, staying well hydrated, avoiding the unnecessary use of painkillers and undergoing routine kidney function tests, particularly for individuals at higher risk.

Experts stress that timely screening, better lifestyle choices and increased public awareness can play a critical role in preventing kidney disease and slowing its progression. With the burden of CKD continuing to rise globally and in India, World Kidney Day serves as an important opportunity to encourage individuals to prioritise kidney health and adopt preventive healthcare practices.

Sources

• The Lancet Study
• MoHFW CKD Guidelines
• PubMed CKD Prevalence Review
• NOTTO Organ Donation Data
• Financial Express Coverage

About Mankind Pharma

Mankind Pharma (BSE: 543904 | NSE: MANKIND) is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence. Mankind operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company is a leading player in the domestic pharmaceuticals business present across acute and chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, gynecology, VMN and respiratory, among others with a strategy to increase chronic presence going ahead. In the consumer healthcare business, the company operates in condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories, among others, with several category-leading brands. Following the acquisition of Bharat Serums and Vaccines Limited, Mankind Pharma has further strengthened its leadership in the domestic women’s health segment. Mankind's distribution network includes a robust field force of 17,700+ professionals, and a reach extending to over five lakh doctors across urban and rural markets. The company has 32 manufacturing facilities manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. Mankind has a consistent track record of product innovation through 6 dedicated R&D facilities backed by more than 730 scientists.